Non-motor complications in late stage Parkinson’s disease: recognition, management and unmet needs

References

• Poewe W, Seppi K, Tanner CM, et al. Parkinson disease. Nat Rev Dis Primers. 2017;3:17013.
   PubMed Web of Science ®Google Scholar
• Titova N, Chaudhuri KR. Non-motor Parkinson disease: new concepts and personalised management. Med J Aust. 2018;208(9):404–409.
   PubMed Web of Science ®Google Scholar
• Holloway RG, Shoulson I, Fahn S, et al. Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial. Arch Neurol. 2004;61(7):1044–1053.
   PubMedGoogle Scholar
• Coelho M, Ferreira JJ. Late-stage Parkinson disease. Nat Rev Neurol. 2012;8(8):435–442.
   PubMed Web of Science ®Google Scholar
• Schapira AHV, Chaudhuri KR, Jenner P. Non-motor features of Parkinson disease. Nat Rev Neurosci. 2017;18(8):509.
   PubMed Web of Science ®Google Scholar
• Sauerbier A, Jenner P, Todorova A, et al. Non motor subtypes and Parkinson’s disease. Parkinsonism Relat Disord. 2016;22(Suppl 1):S41–6.
   PubMed Web of Science ®Google Scholar
• Marras C, Chaudhuri KR. Nonmotor features of Parkinson’s disease subtypes. Mov Disord. 2016;31(8):1095–1102.
   PubMed Web of Science ®Google Scholar
• Antonini A, Stoessl AJ, Kleinman LS, et al. Developing consensus among movement disorder specialists on clinical indicators for identification and management of advanced Parkinson’s disease: a multi-country Delphi-panel approach. Curr Med Res Opin. 2018;34(12):2063–2073.
   PubMed Web of Science ®Google Scholar
• Fasano A, Fung VSC, Lopiano L, et al. Characterizing advanced Parkinson’s disease: OBSERVE-PD observational study results of 2615 patients. BMC Neurol. 2019;19(1):50.
   PubMedGoogle Scholar
• Martinez-Martin P, Ray Chaudhuri K. Comprehensive grading of Parkinson’s disease using motor and non-motor assessments: addressing a key unmet need. Expert Rev Neurother. 2018;18(1):41–50.
   PubMed Web of Science ®Google Scholar
• Hoehn MM, Yahr MD. Parkinsonism: onset, progression, and mortality. Neurology. 1967;17(5):427–442.
   PubMed Web of Science ®Google Scholar
• Chaudhuri KR, Martinez-Martin P, Schapira AH, et al. International multicenter pilot study of the first comprehensive self-completed nonmotor symptoms questionnaire for Parkinson’s disease: the NMSQuest study. Mov Disord. 2006;6(1):916–923. .
   Google Scholar
• Titova N, Martinez-Martin P, Katunina E, et al. Advanced Parkinson’s or “complex phase” Parkinson’s disease? Re-evaluation is needed. J Neural Transm. 2017;6(1):1529–1537.
   Google Scholar
• Chaudhuri KR, Sauerbier A, Rojo JM, et al. The burden of non-motor symptoms in Parkinson’s disease using a self-completed non-motor questionnaire: a simple grading system. Parkinsonism Relat Disord. 2015;21(3):287–291.
   PubMed Web of Science ®Google Scholar
• Pavy-Le Traon A, Amarenco G, Duerr S, et al. The Movement Disorders task force review of dysautonomia rating scales in Parkinson’s disease with regard to symptoms of orthostatic hypotension. Mov Disord. 2011;26(11):1985–1992.
   PubMed Web of Science ®Google Scholar
• Perez-Lloret S, Ciampi de Andrade D, KE L, et al. Rating Scales for Pain in Parkinson’s Disease: critique and Recommendations. Mov Disord Clin Pract. 2016;3(6):527–537.
   PubMed Web of Science ®Google Scholar
• Friedman JH, Alves G, Hagell P, et al. Fatigue rating scales critique and recommendations by the Movement Disorders Society task force on rating scales for Parkinson’s disease. Mov Disord. 2010;25(7):805–822.
   PubMed Web of Science ®Google Scholar
• Schrag A, Barone P, Brown RG, et al. Depression rating scales in Parkinson‘s disease: critique and recommendations. Mov Disord. 2007;22(8):1077–1092.
   PubMed Web of Science ®Google Scholar
• Hogl B, Arnulf I, Comella C, et al. Scales to assess sleep impairment in Parkinson’s disease: critique and recommendations. Mov Disord. 2010;25(16):2704–2716.
   PubMed Web of Science ®Google Scholar
• Mollenhauer B, Zimmermann J, Sixel-Doring F, et al. Baseline predictors for progression 4 years after Parkinson’s disease diagnosis in the De Novo Parkinson Cohort (DeNoPa). Mov Disord. 2019;34(1):67–77.
   PubMed Web of Science ®Google Scholar
• Hely MA, Reid WG, Adena MA, et al. The Sydney multicenter study of Parkinson’s disease: the inevitability of dementia at 20 years. Mov Disord. 2008;23(6):837–844.
   PubMed Web of Science ®Google Scholar
• Williams-Gray CH, Mason SL, Evans JR, et al. The CamPaIGN study of Parkinson’s disease: 10-year outlook in an incident population-based cohort. J Neurol Neurosurg Psychiatry. 2013;84(11):1258–1264.
   PubMed Web of Science ®Google Scholar
• Cholerton BA, Zabetian CP, Quinn JF, et al. Pacific Northwest Udall Center of excellence clinical consortium: study design and baseline cohort characteristics. J Parkinsons Dis. 2013;3(2):205–214.
   PubMedGoogle Scholar
• Litvan I, Goldman JG, Troster AI, et al. Diagnostic criteria for mild cognitive impairment in Parkinson’s disease: movement Disorder Society Task Force guidelines. Mov Disord. 2012;27(3):349–356.
   PubMed Web of Science ®Google Scholar
• Lauze M, Daneault JF, Duval C. The Effects of Physical Activity in Parkinson’s Disease: a Review. J Parkinsons Dis. 2016;6(4):685–698.
   PubMedGoogle Scholar
• da Silva FC, Iop RDR, de Oliveira LC, et al. Effects of physical exercise programs on cognitive function in Parkinson’s disease patients: a systematic review of randomized controlled trials of the last 10 years. PloS One. 2018;13(2):e0193113.
   PubMed Web of Science ®Google Scholar
• Stuckenschneider T, Askew CD, Meneses AL, et al. The Effect of Different Exercise Modes on Domain-Specific Cognitive Function in Patients Suffering from Parkinson’s Disease: a Systematic Review of Randomized Controlled Trials. J Parkinsons Dis. 2019;9(1):73–95.
   PubMedGoogle Scholar
• Bohnen JLB, Muller M, Haugen J, et al. Mentally stimulating activities associate with better cognitive performance in Parkinson disease. J Neural Transm. 2017;124(10):1205–1212.
   PubMed Web of Science ®Google Scholar
• Wang HX, Karp A, Winblad B, et al. Late-life engagement in social and leisure activities is associated with a decreased risk of dementia: a longitudinal study from the Kungsholmen project. Am J Epidemiol. 2002;155(12):1081–1087.
   PubMed Web of Science ®Google Scholar
• Hindle JV, Hurt CS, Burn DJ, et al. The effects of cognitive reserve and lifestyle on cognition and dementia in Parkinson’s disease—a longitudinal cohort study. Int J Geriatr Psychiatry. 2016;31(1):13–23.
   PubMed Web of Science ®Google Scholar
• Goldman JG, Weintraub D. Advances in the treatment of cognitive impairment in Parkinson’s disease. Mov Disord. 2015;30(11):1471–1489.
   PubMed Web of Science ®Google Scholar
• Seppi K, Ray Chaudhuri K, Coelho M, et al. Update on treatments for nonmotor symptoms of Parkinson’s disease-an evidence-based medicine review. Mov Disord. 2019;34(2):180–198.
   PubMed Web of Science ®Google Scholar
• Weintraub D, Caspell-Garcia C, Simuni T, et al. Neuropsychiatric symptoms and cognitive abilities over the initial quinquennium of Parkinson disease. Ann Clin Transl Neurol. 2020;7(4):449–461.
   PubMed Web of Science ®Google Scholar
• Cai X, Campbell N, Khan B, et al. Long-term anticholinergic use and the aging brain. Alzheimers Dement. 2013;9(4):377–385.
   PubMed Web of Science ®Google Scholar
• Marras C, Chaudhuri KR, Titova N, et al. Therapy of Parkinson’s Disease Subtypes. Neurotherapeutics. 2020;17(4):1366–1377.
   PubMed Web of Science ®Google Scholar
• Centi J, Freeman R, Gibbons CH, et al. Effects of orthostatic hypotension on cognition in Parkinson disease. Neurology. 2017;88(1):17–24.
   PubMed Web of Science ®Google Scholar
• Kaminska M, Mery VP, Lafontaine AL, et al. Change in Cognition and Other Non-Motor Symptoms With Obstructive Sleep Apnea Treatment in Parkinson Disease. J Clin Sleep Med. 2018;14(5):819–828.
   PubMed Web of Science ®Google Scholar
• Emre M, Aarsland D, Albanese A, et al. Rivastigmine for dementia associated with Parkinson’s disease. N Engl J Med. 2004;351(24):2509–2518.
   PubMed Web of Science ®Google Scholar
• Emre M, Poewe W, De Deyn PP, et al. Long-term safety of rivastigmine in Parkinson disease dementia: an open-label, randomized study. Clin Neuropharmacol. 2014;37(1):9–16.
   PubMed Web of Science ®Google Scholar
• Dubois B, Tolosa E, Katzenschlager R, et al. Donepezil in Parkinson’s disease dementia: a randomized, double-blind efficacy and safety study. Mov Disord. 2012;27(10):1230–1238.
   PubMed Web of Science ®Google Scholar
• Litvinenko IV, Odinak MM, Mogil’naya VI, et al. Efficacy and safety of galantamine (reminyl) for dementia in patients with Parkinson’s disease (an open controlled trial). Neurosci Behav Physiol. 2008;38(9):937–945.
   PubMedGoogle Scholar
• Leroi I, Overshott R, Byrne EJ, et al. Randomized controlled trial of memantine in dementia associated with Parkinson’s disease. Mov Disord. 2009;24(8):1217–1221.
   PubMed Web of Science ®Google Scholar
• Aarsland D, Ballard C, Walker Z, et al. Memantine in patients with Parkinson’s disease dementia or dementia with Lewy bodies: a double-blind, placebo-controlled, multicentre trial. Lancet Neurol. 2009;8(7):613–618.
   PubMed Web of Science ®Google Scholar
• Emre M, Tsolaki M, Bonuccelli U, et al. Memantine for patients with Parkinson’s disease dementia or dementia with Lewy bodies: a randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2010;9(10):969–977.
   PubMed Web of Science ®Google Scholar
• Martinez-Martin P, Reddy P, Katzenschlager R, et al. EuroInf: a multicenter comparative observational study of apomorphine and levodopa infusion in Parkinson’s disease. Mov Disord. 2015;30(4):510–516.
   PubMed Web of Science ®Google Scholar
• Dafsari HS, Martinez-Martin P, Rizos A, et al. EuroInf 2: subthalamic stimulation, apomorphine, and levodopa infusion in Parkinson’s disease. Mov Disord. 2019;34(3):353–365.
   PubMed Web of Science ®Google Scholar
• Lim EW, Aarsland D, Ffytche D, et al. Amyloid-beta and Parkinson‘s disease. J Neurol. 2019;266(11):2605–2619.
   PubMed Web of Science ®Google Scholar
• van Wamelen D, Politis M, Aarsland D, et al. APOmorphine infusion and aMYLoid deposition in Parkinson’s disease (APOMYL): preliminary clinical and amyloid imaging data (P3.8-032). Neurology. 2019;92(15Supplement):P3.8–032.
   Google Scholar
• Leung IH, Walton CC, Hallock H, et al. Cognitive training in Parkinson disease: a systematic review and meta-analysis. Neurology. 2015;85(21):1843–1851.
   PubMed Web of Science ®Google Scholar
• Lawrence BJ, Gasson N, Johnson AR, et al. Cognitive Training and Transcranial Direct Current Stimulation for Mild Cognitive Impairment in Parkinson’s Disease: a Randomized Controlled Trial. Parkinsons Dis. 2018;4318475.
   PubMed Web of Science ®Google Scholar
• Orgeta V, McDonald KR, Poliakoff E, et al. Cognitive training interventions for dementia and mild cognitive impairment in Parkinson’s disease. Cochrane Database Syst Rev. 2020;2:CD011961.
   PubMedGoogle Scholar
• Nousia A, Martzoukou M, Tsouris Z, et al. The Beneficial Effects of Computer-Based Cognitive Training in Parkinson’s Disease: a Systematic Review. Arch Clin Neuropsychol. 2020;35(4):434–447.
   PubMed Web of Science ®Google Scholar
• Dinkelbach L, Brambilla M, Manenti R, et al. Non-invasive brain stimulation in Parkinson’s disease: exploiting crossroads of cognition and mood. Neurosci Biobehav Rev. 2017;75:407–418.
   PubMed Web of Science ®Google Scholar
• Storch A, Schneider CB, Wolz M, et al. Nonmotor fluctuations in Parkinson disease: severity and correlation with motor complications. Neurology. 2013;80(9):800–809.
   PubMed Web of Science ®Google Scholar
• Antonini A, Leta V, Teo J, et al. Outcome of Parkinson’s Disease Patients Affected by COVID-19. Mov Disord. 2020;35(6):905–908.
   PubMed Web of Science ®Google Scholar
• Sulzer D, Antonini A, Leta V, et al. COVID-19 and possible links with Parkinson’s disease and parkinsonism: from bench to bedside. NPJ Parkinsons Dis. 2020;6(1):18.
   PubMed Web of Science ®Google Scholar
• Chandler SK, Robins JL, Kinser PA. Nonpharmacologic Interventions for the Self-Management of Anxiety in Parkinson’s Disease: a Comprehensive Review. Behav Neurol. 2019;8459579.
   PubMed Web of Science ®Google Scholar
• Pontone GM, Dissanayaka N, Apostolova L, et al. Report from a multidisciplinary meeting on anxiety as a non-motor manifestation of Parkinson’s disease. NPJ Parkinson’s Dis. 2019;5(1):30.
   PubMedGoogle Scholar
• Dobkin RD, Menza M, Allen LA, et al. Cognitive-behavioral therapy for depression in Parkinson’s disease: a randomized, controlled trial. Am J Psychiatry. 2011;168(10):1066–1074.
   PubMed Web of Science ®Google Scholar
• Yang S, Sajatovic M, Walter BL. Psychosocial interventions for depression and anxiety in Parkinson’s disease. J Geriatr Psychiatry Neurol. 2012;25(2):113–121.
   PubMed Web of Science ®Google Scholar
• Troeung L, Egan SJ, Gasson N. A waitlist-controlled trial of group cognitive behavioural therapy for depression and anxiety in Parkinson’s disease. BMC Psychiatry. 2014;14:19.
   PubMed Web of Science ®Google Scholar
• Calleo JS, Amspoker AB, Sarwar AI, et al. A Pilot Study of a Cognitive-Behavioral Treatment for Anxiety and Depression in Patients With Parkinson Disease. J Geriatr Psychiatry Neurol. 2015;28(3):210–217.
   PubMed Web of Science ®Google Scholar
• Weintraub D. Management of psychiatric disorders in Parkinson’s disease: neurotherapeutics — movement Disorders Therapeutics. Neurotherapeutics. 2020;17(4):1511–1524.
   PubMed Web of Science ®Google Scholar
• Schrag A, Hommel A, Lorenzl S, et al. The late stage of Parkinson’s -results of a large multinational study on motor and non-motor complications. Parkinsonism Relat Disord. 2020;75:91–96.
   PubMed Web of Science ®Google Scholar
• Collerton D, Taylor JP. Advances in the treatment of visual hallucinations in neurodegenerative diseases. Future Neurol. 2013;8(4):433–444.
   PubMedGoogle Scholar
• Diederich NJ, Pieri V, Goetz CG. Coping strategies for visual hallucinations in Parkinson’s disease. Mov Disord. 2003;18(7):831–832.
   PubMed Web of Science ®Google Scholar
• Barnes J, Connelly V, Boubert L, et al. Behavioural coping patterns in Parkinson’s patients with visual hallucinations. J Neuropsychol. 2013;7(2):326–334.
   PubMed Web of Science ®Google Scholar
• Thomsen TR, Panisset M, Suchowersky O, et al. Impact of standard of care for psychosis in Parkinson disease. J Neurol Neurosurg Psychiatry. 2008;79(12):1413–1415.
   PubMed Web of Science ®Google Scholar
• Cummings J, Isaacson S, Mills R, et al. Pimavanserin for patients with Parkinson’s disease psychosis: a randomised, placebo-controlled phase 3 trial. Lancet. 2014;383(9916):533–540.
   PubMed Web of Science ®Google Scholar
• Ondo WG, Tintner R, Voung KD, et al. Double-blind, placebo-controlled, unforced titration parallel trial of quetiapine for dopaminergic-induced hallucinations in Parkinson’s disease. Mov Disord. 2005;20(8):958–963.
   PubMed Web of Science ®Google Scholar
• Rabey JM, Prokhorov T, Miniovitz A, et al. Effect of quetiapine in psychotic Parkinson’s disease patients: a double-blind labeled study of 3 months’ duration. Mov Disord. 2007;22(3):313–318.
   PubMed Web of Science ®Google Scholar
• Shotbolt P, Samuel M, Fox C, et al. A randomized controlled trial of quetiapine for psychosis in Parkinson’s disease. Neuropsychiatr Dis Treat. 2009;5:327–332.
   PubMed Web of Science ®Google Scholar
• Zahodne LB, Fernandez HH. Pathophysiology and treatment of psychosis in Parkinson’s disease: a review. Drugs Aging. 2008;25(8):665–682.
   PubMed Web of Science ®Google Scholar
• Kaufmann H, Palma JA. Neurogenic orthostatic hypotension: the very basics. Clin Auton Res. 2017;27(Suppl1):39–43.
   PubMedGoogle Scholar
• Fanciulli A, Campese N, Goebel G, et al. Association of transient orthostatic hypotension with falls and syncope in patients with Parkinson disease. Neurology. 2020;95(21):e2854–e65.
   PubMed Web of Science ®Google Scholar
• Gibbons CH, Schmidt P, Biaggioni I, et al. The recommendations of a consensus panel for the screening, diagnosis, and treatment of neurogenic orthostatic hypotension and associated supine hypertension. J Neurol. 2017;264(8):1567–1582.
   PubMed Web of Science ®Google Scholar
• Espay AJ, LeWitt PA, Hauser RA, et al. Neurogenic orthostatic hypotension and supine hypertension in Parkinson’s disease and related synucleinopathies: prioritisation of treatment targets. Lancet Neurol. 2016;15(9):954–966.
   PubMed Web of Science ®Google Scholar
• Palma JA, Kaufmann H. Orthostatic Hypotension in Parkinson Disease. Clin Geriatr Med. 2020;36(1):53–67.
   PubMed Web of Science ®Google Scholar
• Kaufmann H, Malamut R, Norcliffe-Kaufmann L, et al. The Orthostatic Hypotension Questionnaire (OHQ): validation of a novel symptom assessment scale. Clin Auton Res. 2012;22(2):79–90.
   PubMed Web of Science ®Google Scholar
• Palma JA, Gomez-Esteban JC, Norcliffe-Kaufmann L, et al. Orthostatic hypotension in Parkinson disease: how much you fall or how low you go? Mov Disord. 2015;30(5):639–645.
   PubMed Web of Science ®Google Scholar
• Merola A, Romagnolo A, Rosso M, et al. Orthostatic hypotension in Parkinson’s disease: does it matter if asymptomatic? Parkinsonism & related disorders. 2016;33:65–71.
   Google Scholar
• Palma JA, Kaufmann H. Treatment of autonomic dysfunction in Parkinson disease and other synucleinopathies. Mov Disord. 2018;33(3):372–390.
   PubMed Web of Science ®Google Scholar
• Kaufmann H, Freeman R, Biaggioni I, et al. Droxidopa for neurogenic orthostatic hypotension: a randomized, placebo-controlled, phase 3 trial. Neurology. 2014;83(4):328–335.
   PubMed Web of Science ®Google Scholar
• Schoffer KL, Henderson RD, O’Maley K, et al. Nonpharmacological treatment, fludrocortisone, and domperidone for orthostatic hypotension in Parkinson’s disease. Mov Disord. 2007;22(11):1543–1549.
   PubMed Web of Science ®Google Scholar
• Chen JJ, Han Y, Tang J, et al. Standing and Supine Blood Pressure Outcomes Associated With Droxidopa and Midodrine in Patients With Neurogenic Orthostatic Hypotension: a Bayesian Meta-analysis and Mixed Treatment Comparison of Randomized Trials. Ann Pharmacother. 2018;52(12):1182–1194.
   PubMed Web of Science ®Google Scholar
• Okamoto LE, Diedrich A, Baudenbacher FJ, et al. Efficacy of Servo-Controlled Splanchnic Venous Compression in the Treatment of Orthostatic Hypotension: a Randomized Comparison With Midodrine. Hypertension. 2016;68(2):418–426.
   PubMed Web of Science ®Google Scholar
• Fanciulli A, Goebel G, Metzler B, et al. Elastic Abdominal Binders Attenuate Orthostatic Hypotension in Parkinson‘s Disease. Mov Disord Clin Pract. 2016;3(2):156–160.
   PubMed Web of Science ®Google Scholar
• Kurtis MM, Rajah T, Delgado LF, et al. The effect of deep brain stimulation on the non-motor symptoms of Parkinson’s disease: a critical review of the current evidence. NPJ Parkinsons Dis. 2017;3:16024.
   PubMedGoogle Scholar
• Norcliffe-Kaufmann L, Kaufmann H Autonomic dysfunction in Parkinson’s disease. Parkinson’s Disease: diagnosis, Motor Symptoms and Non-Motor Features: Future Medicine Ltd; 2013. P. 79–98.
   Google Scholar
• Batla A, Tayim N, Pakzad M, et al. Treatment Options for Urogenital Dysfunction in Parkinson’s Disease. Curr Treat Options Neurol. 2016;18(10):45.
   PubMed Web of Science ®Google Scholar
• Madan A, Ray S, Burdick D, et al. Management of lower urinary tract symptoms in Parkinson’s disease in the neurology clinic. Int J Neurosci. 2017;127(12):1136–1149.
   PubMed Web of Science ®Google Scholar
• Gubbiotti M, Conte A, Di Stasi SM, et al. Feasibility of mirabegron in the treatment of overactive bladder in patients affected by Parkinson’s disease: a pilot study. Ther Adv Neurol Disord. 2019;12:1756286419843458.
   Web of Science ®Google Scholar
• Vaughan CP, Burgio KL, Goode PS, et al. Behavioral therapy for urinary symptoms in Parkinson’s disease: a randomized clinical trial. Neurourol Urodyn. 2019;38(6):1737–1744.
   PubMed Web of Science ®Google Scholar
• Dafsari HS, Silverdale M, Strack M, et al. Nonmotor symptoms evolution during 24 months of bilateral subthalamic stimulation in Parkinson’s disease. Mov Disord. 2018;33(3):421–430.
   PubMed Web of Science ®Google Scholar
• American College of Gastroenterology Chronic Constipation Task F. An evidence-based approach to the management of chronic constipation in. North America. Am J Gastroenterol. 2005;100(Suppl 1):S1–4.
   PubMed Web of Science ®Google Scholar
• Mendoza-Velasquez JJ, Flores-Vazquez JF, Barron-Velazquez E, et al. Autonomic Dysfunction in alpha-Synucleinopathies. Front Neurol. 2019;10:363.
   PubMed Web of Science ®Google Scholar
• Chen Z, Li G, Liu J. Autonomic dysfunction in Parkinson’s disease: implications for pathophysiology, diagnosis, and treatment. Neurobiol Dis. 2020;134:104700.
   PubMed Web of Science ®Google Scholar
• Barichella M, Pacchetti C, Bolliri C, et al. Probiotics and prebiotic fiber for constipation associated with Parkinson disease: an RCT. Neurology. 2016;87(12):1274–1280.
   PubMed Web of Science ®Google Scholar
• Zangaglia R, Martignoni E, Glorioso M, et al. Macrogol for the treatment of constipation in Parkinson‘s disease. A randomized placebo-controlled study. Mov Disord. 2007;22(9):1239–1244. .
   PubMed Web of Science ®Google Scholar
• Ondo WG, Kenney C, Sullivan K, et al. Placebo-controlled trial of lubiprostone for constipation associated with Parkinson disease. Neurology. 2012;78(21):1650–1654. .
   PubMed Web of Science ®Google Scholar
• Fasano A, Visanji NP, Liu LW, et al. Gastrointestinal dysfunction in Parkinson’s disease. Lancet Neurol. 2015;14(6):625–639.
   PubMed Web of Science ®Google Scholar
• Reynolds H, Miller N, Walker R. Drooling in Parkinson’s Disease: evidence of a Role for Divided Attention. Dysphagia. 2018;33(6):809–817.
   PubMed Web of Science ®Google Scholar
• van Wamelen DJ, Leta V, Johnson J, et al. Drooling in Parkinson’s Disease: prevalence and Progression from the Non-motor International Longitudinal Study. Dysphagia. 2020;35(6):955–961. .
   PubMed Web of Science ®Google Scholar
• Arbouw ME, Movig KL, Koopmann M, et al. Glycopyrrolate for sialorrhea in Parkinson disease: a randomized, double-blind, crossover trial. Neurology. 2010;74(15):1203–1207. .
   PubMed Web of Science ®Google Scholar
• Chinnapongse R, Gullo K, Nemeth P, et al. Safety and efficacy of botulinum toxin type B for treatment of sialorrhea in Parkinson’s disease: a prospective double-blind trial. Mov Disord. 2012;27(2):219–226.
   PubMed Web of Science ®Google Scholar
• Sridharan K, Sivaramakrishnan G. Pharmacological interventions for treating sialorrhea associated with neurological disorders: a mixed treatment network meta-analysis of randomized controlled trials. J Clin Neurosci. 2018;51:12–17.
   PubMed Web of Science ®Google Scholar
• Egevad G, Petkova VY, Vilholm OJ. Sialorrhea in patients with Parkinson’s disease: safety and administration of botulinum neurotoxin. J Parkinsons Dis. 2014;4(3):321–326.
   PubMedGoogle Scholar
• Valkovic P, Minar M, Singliarova H, et al. Pain in Parkinson´s Disease: a Cross-Sectional Study of Its Prevalence, Types, and Relationship to Depression and Quality of Life. PloS One. 2015;10(8):e0136541. .
   PubMed Web of Science ®Google Scholar
• Buhidma Y, Rukavina K, Chaudhuri KR, et al. Potential of animal models for advancing the understanding and treatment of pain in Parkinson’s disease. NPJ Parkinsons Dis. 2020;6(1):1.
   PubMed Web of Science ®Google Scholar
• Rukavina K, Leta V, Sportelli C, et al. Pain in Parkinsonʼs disease. Curr Opin Neurol. 2019;32(4):579–588. .
   PubMed Web of Science ®Google Scholar
• Ghosh P, Imbriani P, Caputi N, et al. A Dual Centre Study of Pain in Parkinson’s Disease and Its Relationship with Other Non-Motor Symptoms. J Parkinsons Dis. 2020;10(4):1817–1825. .
   PubMedGoogle Scholar
• Tan Y, Tan J, Deng J, et al. Alteration of Basal Ganglia and Right Frontoparietal Network in Early Drug-Café Parkinson’s Disease during Heat Pain Stimuli and Resting State. Front Hum Neurosci. 2015;9:467.
   PubMed Web of Science ®Google Scholar
• Putcha D, Ross RS, Cronin-Golomb A, et al. Altered intrinsic functional coupling between core neurocognitive networks in Parkinson’s disease. Neuroimage Clin. 2015;7:449–455.
   PubMed Web of Science ®Google Scholar
• Chaudhuri KR, Rizos A, Trenkwalder C, et al. King’s Parkinson’s disease pain scale, the first scale for pain in PD: an international validation. Mov Disord. 2015;30(12):1623–1631. .
   PubMed Web of Science ®Google Scholar
• Myers PS, Harrison EC, Rawson KS, et al. Yoga Improves Balance and Low-Back Pain, but Not Anxiety, in People with Parkinson’s Disease. Int J Yoga Therap. 2020;30(1):41–48. .
   PubMedGoogle Scholar
• Nguy V, Barry BK, Moloney N, et al. Exercise-induced hypoalgesia is present in people with Parkinson’s disease: two observational cross-sectional studies. European Journal of Pain (London, England). 2019;23(7):1329–1339.
   PubMed Web of Science ®Google Scholar
• NE A, Moloney N, van Vliet V, et al. The Rationale for Exercise in the Management of Pain in Parkinson’s Disease. J Parkinsons Dis. 2015;10(8):229–239.
   Google Scholar
• Skogar O, Lokk J. Pain management in patients with Parkinson’s disease: challenges and solutions. J Multidiscip Healthc. 2016;9:469–479.
   PubMed Web of Science ®Google Scholar
• Trenkwalder C, Chaudhuri KR, Martinez-Martin P, et al. Prolonged-release oxycodone-naloxone for treatment of severe pain in patients with Parkinson’s disease (PANDA): a double-blind, randomised, placebo-controlled trial. Lancet Neurol. 2015;14(12):1161–1170. .
   PubMed Web of Science ®Google Scholar
• Thakur D, Dickerson S, Kumar Bhutani M, et al. Impact of Prolonged-release Oxycodone/Naloxone on Outcomes Affecting Patients‘ Daily Functioning in Comparison With Extended-release Tapentadol: a Systematic Review. Clin Ther. 2015;37(1):212–224.
   PubMed Web of Science ®Google Scholar
• Guerriero F, Roberto A, Greco MT, et al. Long-term efficacy and safety of oxycodone-naloxone prolonged release in geriatric patients with moderate-to-severe chronic noncancer pain: a 52-week open-label extension phase study. Drug Des Devel Ther. 2016;10:1515–1523.
   PubMed Web of Science ®Google Scholar
• Rascol O, Zesiewicz T, Chaudhuri KR, et al. A Randomized Controlled Exploratory Pilot Study to Evaluate the Effect of Rotigotine Transdermal Patch on Parkinson’s Disease-Associated Chronic Pain. J Clin Pharmacol. 2016;56(7):852–861. .
   PubMed Web of Science ®Google Scholar
• Zella MAS, May C, Muller T, et al. Landscape of pain in Parkinson’s disease: impact of gender differences. Neurol Res. 2019;41(1):87–97. .
   PubMed Web of Science ®Google Scholar
• Buhmann C, Wrobel N, Grashorn W, et al. Pain in Parkinson disease: a cross-sectional survey of its prevalence, specifics, and therapy. J Neurol. 2017;264(4):758–769. .
   PubMed Web of Science ®Google Scholar
• Buhmann C, Kassubek J, Jost WH. Management of Pain in Parkinson’s Disease. J Parkinsons Dis. 2020;10(s1):S37–S48.
   PubMedGoogle Scholar
• Djaldetti R, Yust-Katz S, Kolianov V, et al. The effect of duloxetine on primary pain symptoms in Parkinson disease. Clin Neuropharmacol. 2007;22(9):1239–1244.
   Google Scholar
• Yu SW, Lin SH, Tsai CC, et al. Acupuncture Effect and Mechanism for Treating Pain in Patients With Parkinson’s Disease. Front Neurol. 2019;10:1114.
   PubMed Web of Science ®Google Scholar
• Chakravarthy KV, Chaturvedi R, Agari T, et al. Single arm prospective multicenter case series on the use of burst stimulation to improve pain and motor symptoms in Parkinson’s disease. Bioelectron Med. 2020;6(18). DOI: 10.1186/s42234-020-00055-3.
   Google Scholar
• Loddo G, Calandra-Buonaura G, Sambati L, et al. The Treatment of Sleep Disorders in Parkinson’s Disease: from Research to Clinical Practice. Front Neurol. 2017;8:42.
   PubMed Web of Science ®Google Scholar
• Peeraully T, Yong M-H, Chokroverty S, et al. Sleep and Parkinson’s disease: a review of case-control polysomnography studies. Mov Disord. 2012;27(14):1729–1737.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Zhao JH, Huang DY, et al. Multiple comorbid sleep disorders adversely affect quality of life in Parkinson’s disease patients. NPJ Parkinsons Dis. 2020;6(1):25. .
   PubMed Web of Science ®Google Scholar
• Xu Z, Anderson KN, Saffari SE, et al. Progression of sleep disturbances in Parkinson’s disease: a 5-year longitudinal study. J Neurol. 2021;268(1):312–320.
   PubMed Web of Science ®Google Scholar
• Barone P, Antonini A, Colosimo C, et al. The PRIAMO study: a multicenter assessment of nonmotor symptoms and their impact on quality of life in Parkinson’s disease. Mov Disord. 2009;24(11):1641–1649.
   PubMed Web of Science ®Google Scholar
• JRP Z, During EH. Sleep Issues in Parkinson’s Disease and Their Management. Neurotherapeutics. 2020 Oct;17(4):1480–1494.
   Google Scholar
• Dhawan V, Healy DG, Pal S, et al. Sleep-related problems of Parkinson’s disease. Age Ageing. 2006;35(3):220–228.
   PubMed Web of Science ®Google Scholar
• Gros P, Videnovic A. Sleep and Circadian Rhythm Disorders in Parkinson’s Disease. 2017;3(3):222–234. Curr Sleep Med Rep.
   PubMedGoogle Scholar
• Garcia-Borreguero D, Larrosa O, Bravo M. Parkinson’s disease and sleep. Sleep Med Rev. 2003;7(2):115–129.
   PubMed Web of Science ®Google Scholar
• Liu CF, Wang T, Zhan SQ, et al. Management Recommendations on Sleep Disturbance of Patients with Parkinson’s Disease. Chin Med J (Engl). 2018;131(24):2976–2985.
   PubMed Web of Science ®Google Scholar
• Klingelhoefer L, Rizos A, Sauerbier A, et al. Night-time sleep in Parkinson’s disease — the potential use of Parkinson’s KinetiGraph: a prospective comparative study. Eur J Neurol. 2016;23(8):1275–1288.
   PubMed Web of Science ®Google Scholar
• Pierantozzi M, Placidi F, Liguori C, et al. Rotigotine may improve sleep architecture in Parkinson’s disease: a double-blind, randomized, placebo-controlled polysomnographic study. Sleep Med. 2016;21:140–144.
   PubMed Web of Science ®Google Scholar
• Trenkwalder C, Kies B, Rudzinska M, et al. Rotigotine effects on early morning motor function and sleep in Parkinson’s disease: a double-blind, randomized, placebo-controlled study (RECOVER). Mov Disord. 2011;26(1):90–99.
   PubMed Web of Science ®Google Scholar
• Menza M, Dobkin RD, Marin H, et al. Treatment of insomnia in Parkinson’s disease: a controlled trial of eszopiclone and placebo. Mov Disord. 2010;25(11):1708–1714.
   PubMed Web of Science ®Google Scholar
• Dowling GA, Mastick J, Colling E, et al. Melatonin for sleep disturbances in Parkinson’s disease. Sleep Med. 2005;6(5):459–466.
   PubMed Web of Science ®Google Scholar
• Videnovic A, Klerman EB, Wang W, et al. Timed Light Therapy for Sleep and Daytime Sleepiness Associated With Parkinson Disease: a Randomized Clinical Trial. JAMA Neurol. 2017;74(4):411–418.
   PubMed Web of Science ®Google Scholar
• Zeng BY, Zhao K. Effect of Acupuncture on the Motor and Nonmotor Symptoms in Parkinson’s Disease—A Review of Clinical Studies. CNS Neurosci Ther. 2016;22(5):333–341.
   PubMed Web of Science ®Google Scholar
• Gjerstad MD, Alves G, Wentzel-Larsen T, et al. Excessive daytime sleepiness in Parkinson disease: is it the drugs or the disease? Neurology. 2006;67(5):853–858.
   PubMed Web of Science ®Google Scholar
• Amara AW, Chahine LM, Caspell-Garcia C, et al. Longitudinal assessment of excessive daytime sleepiness in early Parkinson’s disease. J Neurol Neurosurg Psychiatry. 2017;88(8):653–662.
   PubMed Web of Science ®Google Scholar
• Breen DP, Williams-Gray CH, Mason SL, et al. Excessive daytime sleepiness and its risk factors in incident Parkinson’s disease. J Neurol Neurosurg Psychiatry. 2013;84(2):233–234.
   PubMed Web of Science ®Google Scholar
• Zesiewicz TA, Hauser RA. Sleep attacks and dopamine agonists for Parkinson’s disease: what is currently known? CNS Drugs. 2003;17(8):593–600.
   PubMed Web of Science ®Google Scholar
• Hauser RA, Gauger L, Anderson WM, et al. Pramipexole-induced somnolence and episodes of daytime sleep. Mov Disord. 2000;15(4):658–663.
   PubMed Web of Science ®Google Scholar
• Ferreira JJ, Galitzky M, Thalamas C, et al. Effect of ropinirole on sleep onset: a randomized, placebo-controlled study in healthy volunteers. Neurology. 2002;58(3):460–462.
   PubMed Web of Science ®Google Scholar
• Paus S, Brecht HM, Koster J, et al. Sleep attacks, daytime sleepiness, and dopamine agonists in Parkinson’s disease. Mov Disord. 2003;18(6):659–667.
   PubMed Web of Science ®Google Scholar
• Stefani A, Hogl B. Sleep in Parkinson’s disease. Neuropsychopharmacology. 2020;45(1):121–128.
   PubMed Web of Science ®Google Scholar
• Hogl B, Saletu M, Brandauer E, et al. Modafinil for the treatment of daytime sleepiness in Parkinson’s disease: a double-blind, randomized, crossover, placebo-controlled polygraphic trial. Sleep. 2002;25(8):905–909.
   PubMed Web of Science ®Google Scholar
• Adler CH, Caviness JN, Hentz JG, et al. Randomized trial of modafinil for treating subjective daytime sleepiness in patients with Parkinson’s disease. Mov Disord. 2003;18(3):287–293.
   PubMed Web of Science ®Google Scholar
• Postuma RB, Anang J, Pelletier A, et al. Caffeine as symptomatic treatment for Parkinson disease (Café-PD): a randomized trial. Neurology. 2017;89(17):1795–1803.
   PubMed Web of Science ®Google Scholar
• Postuma RB, Lang AE, Munhoz RP, et al. Caffeine for treatment of Parkinson disease: a randomized controlled trial. Neurology. 2012;79(7):651–658.
   PubMed Web of Science ®Google Scholar
• Weintraub D, Mavandadi S, Mamikonyan E, et al. Atomoxetine for depression and other neuropsychiatric symptoms in Parkinson disease. Neurology. 2010;75(5):448–455.
   PubMed Web of Science ®Google Scholar
• Devos D, Krystkowiak P, Clement F, et al. Improvement of gait by chronic, high doses of methylphenidate in patients with advanced Parkinson’s disease. J Neurol Neurosurg Psychiatry. 2007;78(5):470–475.
   PubMed Web of Science ®Google Scholar
• Suzuki K, Miyamoto M, Miyamoto T, et al. Istradefylline improves daytime sleepiness in patients with Parkinson’s disease: an open-label, 3-month study. J Neurol Sci. 2017;380:230–233.
   PubMed Web of Science ®Google Scholar
• Ondo WG, Perkins T, Swick T, et al. Sodium oxybate for excessive daytime sleepiness in Parkinson disease: an open-label polysomnographic study. Arch Neurol. 2008;65(10):1337–1340.
   PubMedGoogle Scholar
• Martinez-Martin P, Wan YM, Ray Chaudhuri K, et al. Impulse control and related behaviors in Parkinson’s disease with dementia. Eur J Neurol. 2020;27(6):944–950.
   PubMed Web of Science ®Google Scholar
• Fauser M, Lohle M, Ebersbach G, et al. Intraindividual Variability of Nonmotor Fluctuations in Advanced Parkinson’s Disease. J Parkinsons Dis. 2015;5(4):737–741.
   PubMedGoogle Scholar
• Martinez-Fernandez R, Schmitt E, Martinez-Martin P, et al. The hidden sister of motor fluctuations in Parkinson’s disease: a review on nonmotor fluctuations. Mov Disord. 2016;31(8):1080–1094.
   PubMed Web of Science ®Google Scholar
• Chaudhuri KR, Rizos A, Sethi KD. Motor and nonmotor complications in Parkinson’s disease: an argument for continuous drug delivery? J Neural Transm. 2013;120(9):1305–1320.
   PubMed Web of Science ®Google Scholar
• Martinez-Martin P, Schrag A, Weintraub D, et al. Pilot Study of the International Parkinson and Movement Disorder Society-sponsored Non-motor Rating Scale (MDS-NMS). Mov Disord Clin Pract. 2019;6(3):227–234.
   PubMed Web of Science ®Google Scholar
• Martinez-Martin P, Rojo-Abuin JM, Weintraub D, et al. Factor Analysis and Clustering of the Movement Disorder Society-Non-Motor Rating Scale. Mov Disord. 2020;35(6):969–975.
   PubMed Web of Science ®Google Scholar
• Chaudhuri KR, Schrag A, Weintraub D, et al. The movement disorder society nonmotor rating scale: initial validation study. Mov Disord. 2020;35(1):116–133.
   PubMed Web of Science ®Google Scholar
• Tenison E, Henderson EJ. Multimorbidity and Frailty: tackling Complexity in Parkinson’s Disease. J Parkinsons Dis. 2020;10(s1):S85–S91.
   PubMedGoogle Scholar